DTIL Precision BioSciences Inc.

9.71
-0.05  -1%
Previous Close 9.76
Open 9.75
Price To Book 2.82
Market Cap 491,626,350
Shares 50,630,932
Volume 4,528
Short Ratio
Av. Daily Volume 124,938

NewsSee all news

  1. Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy

    Phase 1/2a Clinical Trial of Off-The-Shelf Anti-CD20 CAR T Therapy Candidate in Patients with NHL, CLL, and SLL Expected to Begin in Fourth Quarter 2019PBCAR20A has Received Orphan Drug Designation for Mantle Cell

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data due 1Q 2020.
PBCAR0191
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia and R/R non-hodgkin lymphoma
Phase 1/2 trial to be initiated 4Q 2019 with initial data due by 1Q 2020.
PBCAR20A
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Latest News

  1. Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy

    Phase 1/2a Clinical Trial of Off-The-Shelf Anti-CD20 CAR T Therapy Candidate in Patients with NHL, CLL, and SLL Expected to Begin in Fourth Quarter 2019PBCAR20A has Received Orphan Drug Designation for Mantle Cell